NCT01433354 - Long-term, Safety and Tolerability Study of AFQ056 in Adolescent Patients With Fragile X Syndrome (Open-label) | Biotech Hunter

Enrollment

119

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

September 30, 2014

Study Completion Date

September 30, 2014

Conditions

Fragile X Syndrome

Interventions

DRUG

AFQ056

The investigational drug, AFQ056, will be provided as hard gelatin capsules. Two different oral dosage strengths,25mg and 100 mg, identical in appearance, will be used.

Trial Locations (28)

1200

Novartis Investigative Site, Brussels

2145

Novartis Investigative Site, Westmead

2600

Novartis Investigative Site, Glostrup Municipality

3000

Novartis Investigative Site, Leuven

3052

Novartis Investigative Site, Parkville

8091

Novartis Investigative Site, Zurich

10314

Novartis Investigative Site, Staten Island

16147

Novartis Investigative Site, Genova

16374

Novartis Investigative Site, Spånga

29009

Novartis Investigative Site, Málaga

30033

Novartis Investigative Site, Decatur

35128

Novartis Investigative Site, Padua

37212

Novartis Investigative Site, Nashville

52621

Novartis Investigative Site, Ramat Gan

55131

Novartis Investigative Site, Mainz

60612

Novartis Investigative Site, Chicago

69677

Novartis Investigative Site, Bron

72076

Novartis Investigative Site, Tübingen

80639

Novartis Investigative Site, München

95817

Novartis Investigative Site, Sacramento

97070

Novartis Investigative Site, Würzburg

02115

Novartis Investigative Site, Boston

68198-5575

Novartis Investigative Site, Omaha

3015 CE

Novartis Investigative Site, Rotterdam

08208

Novartis Investigative Site, Sabadell

08190

Novartis Investigative Site, Sant Cugat del Vallès

Unknown

Novartis Investigative Site, Lausanne

EH10 5HF

Novartis Investigative Site, Edinburgh